AR056821A1 - Derivados de piperidina sustituida por heteroarilo - Google Patents
Derivados de piperidina sustituida por heteroariloInfo
- Publication number
- AR056821A1 AR056821A1 ARP060105273A ARP060105273A AR056821A1 AR 056821 A1 AR056821 A1 AR 056821A1 AR P060105273 A ARP060105273 A AR P060105273A AR P060105273 A ARP060105273 A AR P060105273A AR 056821 A1 AR056821 A1 AR 056821A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- optionally substituted
- carbonyl
- dihydro
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
REIVINDICACIoN 1.- Compuestos de formula (I) en la que X es C(R8R9), NR10, O, S, S(O), S(O2); R1 es fenilo opcionalmente sustituido con de 1 a 3 sustituyentes elegidos entre el grupo formado por halogeno, hidroxi, alquilo inferior, hidroxialquilo inferior, fluoralquilo inferior, alcoxi inferior y CN; R2 es hidrogeno o alquilo inferior; R3 y R4 con independencia entre sí son hidrogeno, halogeno, alquilo inferior o alcoxi inferior, o R3 y R4 juntos con =O para formar un grupo carbonilo junto con el átomo de carbono al que están unidos; R5 y R6 con independencia entre sí son hidrogeno, halogeno, alquilo inferior o alcoxi inferior, o R5 y R6 juntos son =O para formar un grupo carbonilo junto con el átomo de carbono al que están unidos; R7 es oxadiazolilo o triazolilo, dichos oxadiazolilo o triazolilo están sustituidos por R11 y opcionalmente sustituidos por R12; R8 y R9 con independencia ente sí son hidrogeno, halogeno, hidroxi, alquilo inferior, alcoxi inferior; o R8 y R9 están unidos entre sí y -R8 -R9- es -(CH2)2-7- para formar un anillo junto con el átomo de carbono al que están unidos; R10 es hidrogeno, alquilo inferior, (alquilo inferior)-carbonilo o alquilsulfonilo inferior; R11 es arilo o heteroarilo elegido entre el grupo formado por piridinilo, pirazinilo, pirimidinilo, piridinil-2-ona, oxadiazolilo,indazolilo, 1,3-dihidro-bencimidazol-2-ona, 1,3-dihidro-indol-2-ona, benzotriazolilo, imidazopiridinilo, triazolpiridinilo, tetrazolpiridinilo, bencimidazolilo, 2-oxo-2,3-dihidro-1H-indol-5-ilo, pirimidin-4-ona, furanilo, tiadiazolilo, pirazolilo, isoxazolilo, pirimidina-2,4-diona, benzooxazin-3-ona, 1,4-dihidro-benzooxazin-2-ona, indolilo, tiofenilo, oxazolilo, benzooxazin-2-ona, 3,4-dihidro-quinazolin-2- ona, piridazinilo, quinoxalinilo, benzotiazolilo, benzotiadiazolilo, naftiridinilo, cinolinilo, 1,4-dihidro-quinoxalina-2,3-diona y 1,2-dihidro-indazol-3-ona, dicho arilo o heteroarilo está opcionalmente sustituido con de 1 a 3 sustituyentes elegidos entre el grupo formado por alquilo inferior, hidroxi, B(OH)2, carboxi-alcoxi inferior, carbamoil-alcoxi inferior, ciano, hidroxialquilo inferior, fluoralquilo inferior, alcoxi inferior, halogeno, S(O2)R13, C(O)R14, NO2, NR15R16, imidazolilo, tetrazolilo, pirrolilo, fenil-alcoxi inferior, [1,3,4]oxadiazol-2-ona, oxadiazolilo, triazolilo e isoxazolilo, dicho imidazolilo está opcionalmente sustituido con alquilo inferior y dicho fenil-alcoxi inferior está opcionalmente sustituido con hidroxi, halogeno, alquilo inferior, alcoxi inferior o fluoralquilo inferior y dicho pirazolilo está opcionalmente sustituido con alquilo inferior y dicho isoxazolilo está opcionalmente sustituido con alquilo inferior; R12 es hidrogeno o alquilo inferior; R13 es alquilo inferior, NR17R18 o fluoralquilo inferior; R14 es OH, NR19R20, alcoxi inferior, alqueniloxi inferior o alquilo inferior; R15 y R16 con independencia entre sí son hidrogeno, alquilo inferior, (alquilo inferior)-carbonilo, alquilo inferior-SO2, (alqueniloxi inferior)-carbonilo, NH2-carbonilo, (alquilo inferior)-NH-carbonilo, (alquilo inferior)2N-carbonilo o fenil-alquilo, dicho fenil-alquilo inferior está opcionalemente sustituido con hidroxi, halogeno, alquilo inferior, alcoxi inferior o fluoralquilo inferior; o NR15R16 es un heterociclilo elegido entre el grupo formado por morfolinilo, tiomorfolinilo, 1,1-dioxo-tiomorfolinilo, piperidinilo, piperidin-2-ona, peperazin-2-ona, 8-oxa-3-aza- biciclo[3.2.1]octilo, piperazinilo, pirrolidinilo, 1,1-dioxo-isotiazolidinilo, pirrolidin-2-ona, imidazolidina-2,4-diona, 2,4-dihidro[1,2,4]triazol-3-ona, pirrolidina-2,5-diona, azetin-2-ona y 1,3-dihidro-imidazol-2-ona, dicho heterociclilo está opcionalmente sustituido con hidroxialquilo inferior o (alquilo inferior)-carbonilo; R17 y R18 con independencia entre sí son hidrogeno, alquilo inferior, hidroxialquilo inferior, alcoxi inferior-alquilo inferior; o NR17R18 es morfolinilo; R19 y R20 con independencia entre sí son hidrogeno, alquilo inferior, cicloalquilo, hidroxialquilo inferior, alcoxi inferior-alquilo inferior, (alquilo inferior)2N-alquilo inferior, piridinil-alquilo inferior o ciano-alquilo inferior; o NR19R20 es un heterociclilo elegido entre el grupo formado por morfolinilo, pirrolidinilo, 8-oxa-3-aza-biciclo[3.2.1]octilo, piperidinilo, piperazinilo, piperazin-2-ona, tiazolidinilo, tiomorfolinilo, 1,3,8-triaza-espiro[4,5]decano-2,4diona y espiro(1-ftalano)- piperidin-4-ilo, dicho heterociclilo está opcionalmente sustituido con hidroxi, (alquilo inferior)-S(O2), alquilo inferior, (alquilo inferior)-carbonilo, carboxi, carbamoílo, alcoxi inferior-carbonilo, ciano, fenilo, piridinilo o alcoxi inferior; y las sales y ésteres farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05111560 | 2005-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR056821A1 true AR056821A1 (es) | 2007-10-24 |
Family
ID=37719360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060105273A AR056821A1 (es) | 2005-12-01 | 2006-11-29 | Derivados de piperidina sustituida por heteroarilo |
Country Status (20)
Country | Link |
---|---|
US (1) | US7645776B2 (es) |
EP (1) | EP1959951B1 (es) |
JP (1) | JP4855478B2 (es) |
KR (1) | KR101135310B1 (es) |
CN (1) | CN101321525B (es) |
AR (1) | AR056821A1 (es) |
AT (1) | ATE452635T1 (es) |
AU (1) | AU2006319247B2 (es) |
BR (1) | BRPI0619086A2 (es) |
CA (1) | CA2630460C (es) |
DE (1) | DE602006011363D1 (es) |
DK (1) | DK1959951T3 (es) |
ES (1) | ES2335698T3 (es) |
NO (1) | NO20082388L (es) |
PL (1) | PL1959951T3 (es) |
PT (1) | PT1959951E (es) |
RU (1) | RU2396269C2 (es) |
TW (1) | TWI358409B (es) |
WO (1) | WO2007063012A1 (es) |
ZA (1) | ZA200804393B (es) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200811137A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators II |
JO3598B1 (ar) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
KR100847448B1 (ko) * | 2007-03-22 | 2008-07-21 | 한국화학연구원 | 3-아릴-5-알킬-1,2,4-옥사다이아졸 유도체, 그 제조방법 및이를 포함하는 비만 예방 또는 치료용 조성물 |
ES2369315T3 (es) * | 2007-06-01 | 2011-11-29 | F. Hoffmann-La Roche Ag | Derivados de piperidina-amida. |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
PE20091838A1 (es) * | 2008-04-09 | 2009-12-18 | Infinity Pharmaceuticals Inc | Inhibidores de amida hidrolasa de acido graso |
RU2011123647A (ru) | 2008-11-10 | 2012-12-20 | Вертекс Фармасьютикалз Инкорпорейтед | Соединения, полезные в качестве ингибиторов atr киназы |
CA3013000C (en) | 2008-12-19 | 2022-12-13 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of atr kinase |
ES2493916T3 (es) | 2009-04-07 | 2014-09-12 | Infinity Pharmaceuticals, Inc. | Inhibidores de hidrolasa de amida de ácidos grasos |
US8541581B2 (en) | 2009-04-07 | 2013-09-24 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
CA2816448A1 (en) | 2009-05-20 | 2010-11-25 | Heart Metabolics Limited | Treatment of heart failure with normal ejection fraction |
CN102439523B (zh) | 2009-07-23 | 2015-01-07 | 道康宁公司 | 用于双重图案化的方法和材料 |
MX336742B (es) | 2010-02-03 | 2016-01-29 | Infinity Pharmaceuticals Inc | Inhibidores de amida hidrolasa de acido graso. |
CA2798760A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as inhibitors of atr kinase |
EP2568984A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
SG185524A1 (en) | 2010-05-12 | 2012-12-28 | Vertex Pharma | Compounds useful as inhibitors of atr kinase |
WO2011143419A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Pyrazines useful as inhibitors of atr kinase |
EP2569286B1 (en) | 2010-05-12 | 2014-08-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
EP2569287B1 (en) | 2010-05-12 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
EP2585468A1 (en) | 2010-06-23 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
BR112013022761B8 (pt) * | 2011-03-08 | 2023-01-17 | 3 V Biosciences Inc | Compostos moduladores heterocíclicos de síntese de lipídios, suas composições e usos |
US20170119786A1 (en) | 2011-03-08 | 2017-05-04 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
TWI522348B (zh) | 2011-03-08 | 2016-02-21 | 3 V生物科技公司 | 脂質合成之雜環調節劑 |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US9624173B2 (en) | 2011-03-08 | 2017-04-18 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
JP2014510151A (ja) | 2011-04-05 | 2014-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ(trakinase)阻害剤として有用なアミノピラジン化合物 |
US8822469B2 (en) | 2011-06-22 | 2014-09-02 | Vertex Pharmaceuticals Incorporated | Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase |
EP2723746A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013049726A2 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Processes for making compounds useful as inhibitors of atr kinase |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
CA2850491C (en) | 2011-09-30 | 2020-10-27 | Vertex Pharmaceuticals Incorporated | Treating pancreatic cancer and non-small cell lung cancer with atr inhibiors |
CA2850564A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2751088B1 (en) | 2011-09-30 | 2016-04-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013071090A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
JP2015502925A (ja) | 2011-11-09 | 2015-01-29 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用なピラジン化合物 |
EP2776429A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013071088A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
MX358818B (es) | 2012-04-05 | 2018-09-05 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa ataxia telangiectasia mutada y rad3 relacionados (atr) y terapias de combinacion de estos. |
ES2738823T3 (es) | 2012-07-03 | 2020-01-27 | 3 V Biosciences Inc | Moduladores heterocíclicos de la síntesis de lípidos |
WO2014055756A1 (en) | 2012-10-04 | 2014-04-10 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
ES2946360T3 (es) | 2012-12-07 | 2023-07-17 | Vertex Pharma | Pirazolo[1,5-a]pirimidinas útiles como inhibidores de ATR quinasa para el tratamiento de enfermedades de cáncer |
CA2895905A1 (en) | 2012-12-21 | 2014-06-26 | Zenith Epigenetics Corp. | Novel heterocyclic compounds as bromodomain inhibitors |
WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
BR112015031073B1 (pt) | 2013-06-21 | 2022-11-29 | Zenith Epigenetics Ltd | Compostos inibidores bicíclicos de bromodomínio e composição farmacêutica contendo os referidos compostos |
US9636328B2 (en) * | 2013-06-21 | 2017-05-02 | Zenith Epigenetics Ltd. | Substituted bicyclic compounds as bromodomain inhibitors |
KR20160038008A (ko) | 2013-07-31 | 2016-04-06 | 제니쓰 에피제네틱스 코포레이션 | 브로모도메인 억제제로서 신규 퀴나졸리논 |
RU2687276C2 (ru) | 2013-12-06 | 2019-05-13 | Вертекс Фармасьютикалз Инкорпорейтед | Соединения, пригодные для использования в качестве ингибиторов atr киназы |
EP3083583B1 (en) | 2013-12-20 | 2020-11-18 | Sagimet Biosciences Inc. | Heterocyclic modulators of lipid synthesis and combinations thereof |
LT3152212T (lt) | 2014-06-05 | 2020-05-11 | Vertex Pharmaceuticals Inc. | Radioaktyviai žymėti 2-amino-6-fluor-n-[5-fluor-piridin-il]- pirazolo[1,5-a]pirimidin-3-karboksamido junginio dariniai, naudingi kaip atr kinazės inhibitoriai, minėto junginio gamybos būdas ir jo skirtingos kietos formos |
SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
JP6691909B2 (ja) | 2014-08-15 | 2020-05-13 | サギメット バイオサイエンシーズ インコーポレイテッド | 薬物耐性癌の治療で用いるための脂肪酸シンターゼ阻害剤 |
US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
WO2016092375A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Corp. | Substituted heterocycles as bromodomain inhibitors |
US10231953B2 (en) | 2014-12-17 | 2019-03-19 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
CN107428728A (zh) | 2015-03-19 | 2017-12-01 | 3-V生物科学股份有限公司 | 脂质合成的杂环调节剂 |
CA3000684A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
US11078528B2 (en) | 2015-10-12 | 2021-08-03 | Advanced Cell Diagnostics, Inc. | In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto |
EP3373732A1 (en) | 2015-11-13 | 2018-09-19 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
WO2017081312A1 (en) | 2015-11-13 | 2017-05-18 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
WO2018089904A1 (en) | 2016-11-11 | 2018-05-17 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
AU2020240059A1 (en) * | 2019-03-20 | 2021-10-28 | Goldfinch Bio, Inc. | Pyridazinones and methods of use thereof |
AU2022269825A1 (en) | 2021-05-04 | 2023-11-09 | 2N Pharma Aps | Diazepane derivatives, processes for their preparation, and uses thereof for the amelioration, prevention and/or treatment of mental and neurological diseases |
WO2023285349A1 (en) * | 2021-07-12 | 2023-01-19 | 2N Pharma Aps | Carnitine-palmitoyl-transferase-1 (cpt-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196418A (en) * | 1992-02-14 | 1993-03-23 | Board Of Supervisors, Louisiana State University Agricultural & Mechanical College | Hemicholinium lipids and use thereof |
AU3464497A (en) * | 1996-07-02 | 1998-01-21 | Sang Sup Jew | 2-hydroxypropionic acid derivative and its manufacturing method |
US6207665B1 (en) * | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
AU4167099A (en) * | 1998-06-19 | 2000-01-05 | Nissan Chemical Industries Ltd. | Heterocyclic compounds as hypoglycemic agents |
JP2001031652A (ja) * | 1998-06-19 | 2001-02-06 | Nissan Chem Ind Ltd | 六員環複素環類 |
JP2003535034A (ja) * | 1999-11-12 | 2003-11-25 | ギルフォード ファーマシューティカルズ インコーポレイテッド | ジペプチジルペプチダーゼiv阻害剤並びにジペプチジルペプチダーゼiv阻害剤の製造及び使用法 |
US20050256159A1 (en) * | 2002-10-11 | 2005-11-17 | Astrazeneca Ab | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors |
-
2006
- 2006-11-22 AU AU2006319247A patent/AU2006319247B2/en not_active Ceased
- 2006-11-22 ES ES06819660T patent/ES2335698T3/es active Active
- 2006-11-22 JP JP2008542722A patent/JP4855478B2/ja not_active Expired - Fee Related
- 2006-11-22 BR BRPI0619086-3A patent/BRPI0619086A2/pt not_active IP Right Cessation
- 2006-11-22 EP EP06819660A patent/EP1959951B1/en not_active Not-in-force
- 2006-11-22 CN CN2006800453448A patent/CN101321525B/zh not_active Expired - Fee Related
- 2006-11-22 PT PT06819660T patent/PT1959951E/pt unknown
- 2006-11-22 AT AT06819660T patent/ATE452635T1/de active
- 2006-11-22 DK DK06819660.9T patent/DK1959951T3/da active
- 2006-11-22 WO PCT/EP2006/068745 patent/WO2007063012A1/en active Application Filing
- 2006-11-22 CA CA2630460A patent/CA2630460C/en not_active Expired - Fee Related
- 2006-11-22 KR KR1020087015998A patent/KR101135310B1/ko not_active IP Right Cessation
- 2006-11-22 DE DE602006011363T patent/DE602006011363D1/de active Active
- 2006-11-22 RU RU2008126398/04A patent/RU2396269C2/ru not_active IP Right Cessation
- 2006-11-22 PL PL06819660T patent/PL1959951T3/pl unknown
- 2006-11-29 TW TW095144178A patent/TWI358409B/zh not_active IP Right Cessation
- 2006-11-29 AR ARP060105273A patent/AR056821A1/es unknown
- 2006-11-29 US US11/605,904 patent/US7645776B2/en not_active Expired - Fee Related
-
2008
- 2008-05-21 ZA ZA200804393A patent/ZA200804393B/xx unknown
- 2008-05-26 NO NO20082388A patent/NO20082388L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW200804357A (en) | 2008-01-16 |
ATE452635T1 (de) | 2010-01-15 |
PT1959951E (pt) | 2010-03-02 |
CA2630460A1 (en) | 2007-06-07 |
CN101321525B (zh) | 2013-01-30 |
ZA200804393B (en) | 2009-04-29 |
TWI358409B (en) | 2012-02-21 |
DE602006011363D1 (de) | 2010-02-04 |
JP2009517438A (ja) | 2009-04-30 |
KR101135310B1 (ko) | 2012-04-12 |
EP1959951B1 (en) | 2009-12-23 |
CA2630460C (en) | 2013-01-08 |
WO2007063012A1 (en) | 2007-06-07 |
KR20080072097A (ko) | 2008-08-05 |
CN101321525A (zh) | 2008-12-10 |
JP4855478B2 (ja) | 2012-01-18 |
NO20082388L (no) | 2008-08-26 |
RU2396269C2 (ru) | 2010-08-10 |
DK1959951T3 (da) | 2010-03-01 |
ES2335698T3 (es) | 2010-03-31 |
BRPI0619086A2 (pt) | 2011-09-20 |
AU2006319247B2 (en) | 2010-03-11 |
US20070129544A1 (en) | 2007-06-07 |
US7645776B2 (en) | 2010-01-12 |
RU2008126398A (ru) | 2010-01-10 |
PL1959951T3 (pl) | 2010-06-30 |
EP1959951A1 (en) | 2008-08-27 |
AU2006319247A1 (en) | 2007-06-07 |
AU2006319247A8 (en) | 2008-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR056821A1 (es) | Derivados de piperidina sustituida por heteroarilo | |
RU2503676C2 (ru) | Пирролопиразиновые ингибиторы киназы | |
AR035401A1 (es) | El uso de compuestos derivados de feniletenilo y feniletinilo; compuestos derivados de feniletinilo; compuestos derivados de feniletenilo; un procedimiento para la elaboracion de los mismos; y medicamentos que los contienen | |
JP2009538896A5 (es) | ||
RU2003106193A (ru) | Способ лечения аллергий с использованием замещенных пиразолов | |
AR053406A1 (es) | Derivados de piperidina como inhibidores de renina. composiciones farmaceuticas | |
ES2409109T3 (es) | Derivados de pirimidina- y triazina-sulfonamida como inhibidores del receptor de la bradiquinina b1 (b1r) para el tratamiento del dolor | |
RU2405771C2 (ru) | Гетероциклические замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1 | |
RU2005117383A (ru) | Производные фенилаланина в качестве ингибиторов дипептидилпептидазы для лечения или профилактики диабета | |
PE20040265A1 (es) | Compuestos de quinazolina utiles en terapia | |
JP2011516512A5 (ja) | 新規な置換スピロ[シクロアルキル−1,3'−インドール]−2'(1'H)−オン誘導体およびp38マイトジェン活性化タンパク質キナーゼ阻害剤としてのそれらの使用 | |
IL277579B (en) | Piperidinone derivatives as mdm2 inhibitors for cancer therapy | |
PT2066659E (pt) | Derivados de sulfonamida substituídos | |
CA2705405A1 (en) | New compounds | |
ES2319642T3 (es) | Derivados 1,4-di-piperidina-4-il-piperazina sustituidos y su uso como antagonistas de la neuroquinina. | |
RU2007133655A (ru) | Замещенные бис-арильные и гетероарильные соединения в качестве селективных антагонистов 5нт2а | |
IL216247A (en) | Tetrahydrobenzazepine-conjugated and terroyl-containing and used to prevent the reabsorption of norepinephrine, dopamine and serotonin | |
JP2013526536A5 (es) | ||
RU2003107016A (ru) | Замещенные пиразолы | |
PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
AR076562A1 (es) | Derivados de ciclopenta (c) pirrol-2- carboxilatos, su preparacion y su aplicacion en terapeutica | |
AR063529A1 (es) | Compuestos de pirazolina | |
PE20091090A1 (es) | Derivados de piperidina como agonistas de receptores muscarinicos | |
JP2010524984A5 (es) | ||
PE20080543A1 (es) | Nuevos derivados de fenilo, piridina y quinolina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |